21 May 2009
Evaluation differents immunosuppressive protocols in patients after kidney transplantation
L Zair, T Sulikowski, M Kamiński, Z Ziętek, S Zeair, A Sierocka, K Tejchman, M Wiśniowski, M Szałata, K Kłoda, M OstrowskiAnn Transplant 2009; 14(1): 51-51 :: ID: 880386
Abstract
Prevention and control of renal allograft rejection have been some of the main problems since the first kidney transplant. Common use of selective immunosuppressive agents became an effective and safe way of treatment Nevertheless comparing immunosuppressive protocols containing different
types of drugs is still a pivotal aim of many studies. Here we are presenting the experience from two different centres in Szczecin.The aim of our study was to compare two immunosuppressive protocols: Tac MMF steroids with Cs Aza steroids and their efficacy, incidence of acute rejection, side effects, incidence of IGF, DGF and serum creatinine concentrations after 1 month and 1 year. We have investigated medical records of 1248 patients, treated between the years 1990-2007 in two different centres in Szczecin. 553 patients were selected and divided into two groups - Tac MMF steroids protocol recipients (n=135) and Cs Aza steroids protocol recipients (n=418). We observed higher incidence of IGF with Tac MMF steroids protocol use, and higher incidence of DGF with Cs Aza steroids protocol use. There were no significant differences between immunosuppressive protocols and patients gender in regard to episodes of acute rejection. The incidence of acute rejection was higher in younger patients. Side effects after immunosuppressive treatment were more common in Tac MMF steroids protocol recipients and in younger patients. There were no significant differences between the serum creatinine concentrations after 1 month and 1 year in regard to both of the protocols.
Keywords: Immunosuppression, Kidney Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






